BackOpiant Pharmaceuticals Overview

Opiant Pharmaceuticals Intangible Assets

Track Opiant Pharmaceuticals's intangible assets ($11K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$10598.00
11.47% YoYΔ $-1373.00 vs prior year quarter

Peer trimmed avg / median

Loading

Opiant Pharmaceuticals Intangible Assets History

Loading

Opiant Pharmaceuticals vs. peers: Intangible Assets Comparison

Loading

Opiant Pharmaceuticals Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Opiant Pharmaceuticals (OPNT) FAQ

Opiant Pharmaceuticals's intangible assets stands at $11K as of September 2022. That compares with $12K in the prior-year period — down 11.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Opiant Pharmaceuticals reported $11K in intangible assets versus $12K a year earlier — a 11.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $12K in the prior-year period — down 11.5% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Opiant Pharmaceuticals's intangible assets evolved across reporting periods, while the comparison chart places OPNT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, intangible assets is commonly used to spot outliers. Opiant Pharmaceuticals's reading of $11K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.